# Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients

> **NCT03256331** · PHASE1 · TERMINATED · sponsor: **Belx Bio-Pharmaceutical (Taiwan) Corporation** · enrollment: 23 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BEL-X-HG

## Key facts

- **NCT ID:** NCT03256331
- **Lead sponsor:** Belx Bio-Pharmaceutical (Taiwan) Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-21
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-03-30
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** In the light of the on-going COVID-19 pandemic and the resulted difficulty in patient recruitment.
- **Last updated:** 2020-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03256331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03256331, "Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03256331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*